Capitol Cardiology Associates

Lanham, Maryland 20706

4 studies enrolling now · 11 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease, Heart Failure, Hypercholesterolaemia, Hypertension, Lipoprotein Disorder, Primary Prevention of Atherosclerotic Cardiovascular Disease, Resistant Hypertension

Studies at this site

• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia — Recruiting now
• Pelacarsen Roll-over Extension Program — Recruiting now
• Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD — Completed
• A Study of DII235 in Adults With Elevated Lipoprotein(a) — Running, not enrolling
• Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry) — Stopped early
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients — Running, not enrolling
• An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. — Completed